Αρχειοθήκη ιστολογίου

Σάββατο 22 Ιουνίου 2019

Ca


Individualized prediction of leukemia‐free survival after autologous stem cell transplantation in acute myeloid leukemia
Background Autologous stem cell transplantation (ASCT) is a potential consolidation therapy for acute myeloid leukemia (AML). This study was designed to develop a prediction model for leukemia‐free survival (LFS) in a cohort of patients with de novo AML treated with ASCT during their first complete remission. Methods This was a registry study of 956 patients reported to the European Society for Blood and Marrow Transplantation. The primary outcome was LFS. Multivariate Cox regression modeling...
Cancer
10m
Cancers, Vol. 11, Pages 873: Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence
Cancers, Vol. 11, Pages 873: Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current EvidenceCancers doi: 10.3390/cancers11060873Authors:Pierre M. GholamRenuka IyerMatthew S. JohnsonHepatocellular carcinoma (HCC) is a leading cause of new cancer diagnoses in the United States, with an incidence that is expected to rise. The etiology of HCC is varied and can lead to differences between patients in terms of presentation and natural history....
Cancers
2h
Cytotoxic T-cells and their activation status are independent prognostic markers in meningiomas
Purpose: Clinically aggressive meningiomas (MGMs) are rare but treatment-resistant tumors in need for more effective therapies. Since tumor-infiltrating T-lymphocytes (TILs) are essential for successful immunotherapy, we assessed TIL numbers and their activation status in primary (p-) and recurrent (r-)MGMs and their impact on survival. Experimental Design: Presence of TILs was analyzed in 202 clinically well-annotated cases (n = 123 pMGMs and n = 79 rMGMs) focusing on higher-grade MGMs (n = 97 WHO°II,...
Clinical Cancer Research Online First Articles
4h
Integrative copy number analysis of uveal melanoma reveals novel candidate genes involved in tumorigenesis including a tumor suppressor role for PHF10/BAF45a
Purpose: Uveal melanoma (UM) is a primary malignancy of the eye with oncogenic mutations in GNAQ, GNA11, or CYSLTR2, and additional mutations in BAP1 (usually associated with LOH of Chr 3), SF3B1 or EIF1AX. There are other characteristic chromosomal alterations, but their significance is not clear. Experimental Design: To investigate genes driving chromosomal alterations we integrated copy number, transcriptome and mutation data from three cohorts and followed up key findings. Results: We observed...
Clinical Cancer Research Online First Articles
4h
Exercise as a Candidate Anti-Tumor Strategy: A Window into the Future
Observational findings suggest exercise is associated with improved outcomes in early-stage breast cancer. However, whether exercise has biological activity in patients with breast cancer has not been investigated. Pre-operative window of opportunity studies provide a setting in which to test the short-term effects of novel treatment strategies on validated surrogates.
Clinical Cancer Research Online First Articles
4h
Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors
Purpose: Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. KRAS requires farnesylation for membrane localization and cancer-causing activity prompting the development of farnesyltransferase inhibitors (FTIs) as anti-cancer agents. However, KRAS becomes geranylgeranylated and active when cancer cells are treated with FTIs. To overcome this geranylgeranylation-dependent resistance to FTIs, we designed FGTI-2734, a RAS C-terminal...
Clinical Cancer Research Online First Articles
4h
Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations.
Purpose: Uveal melanomas (UMs) are genetically simple tumors carrying few copy number alterations (CNAs) and a low mutation burden, except in rare MBD4-deficient, hypermutated cases. The genomics of UM metastatic progression has not been described. We assessed the genetic heterogeneity of primary and metastatic MBD4-proficient and deficient UMs. Experimental Design: We prospectively collected 75 metastatic and 16 primary samples from 25 consecutive UM patients, and performed whole-exome sequencing....
Clinical Cancer Research Online First Articles
4h
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Purpose: LV305 is a modified, third generation, non-replicating, integration-deficient lentivirus-based vector designed to selectively transduce dendritic cells in vivo. LV305 induces expression of the NY-ESO-1 cancer testis antigen in dendritic cells, promoting immune responses against NY-ESO-1-expressing tumors. This phase 1 study evaluated the safety, immunogenicity, and preliminary efficacy of LV305 in patients with sarcoma or other solid tumors. Experimental Design: Adults with previously-treated,...
Clinical Cancer Research Online First Articles
4h
Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data
Purpose: Conflicting data have been reported on the prognostic value of PD-L1 protein and gene expression in breast cancer. Experimental Design: Medline, Embase, Cochrane Library and Web of Science Core Collection were searched and data were extracted independently by two researchers. Outcomes included pooled PD-L1 protein positivity in tumor cells, immune cells or both, per subtype and per antibody used; and its prognostic value for disease-free and overall survival. A pooled gene expression analysis...
Clinical Cancer Research Online First Articles
4h
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma
Purpose: Radiation therapy (RT) has long been and remains the only treatment option for diffuse intrinsic pontine glioma (DIPG). However, all patients show evidence of disease progression within months of completing radiation therapy. No further clinical benefit has been achieved using alternative radiation strategies. Here we tested the hypothesis that histone demethylase inhibition by GSK-J4 enhances radiation-induced DNA damage, making it a potential radiosensitizer in the treatment of DIPG....
Clinical Cancer Research Online First Articles
4h
Targeting Topoisomerase I in the Era of Precision Medicine
Irinotecan and topotecan have been widely used as anticancer drugs for the past 20 years. Due to their selectivity as topoisomerase I (TOP1) inhibitors that trap TOP1 cleavage complexes (TOP1CCs), camptothecins are also widely used to elucidate the DNA repair pathways associated with DNA-protein crosslinks and replication stress. This review summarizes the basic molecular mechanisms of action of TOP1 inhibitors, their current use and limitations as anticancer agents. We introduce new therapeutic...
Clinical Cancer Research Online First Articles
4h
When cancer vaccines go viral
Induction of antitumor responses by vaccines requires strong immunogens. Heterologous viral prime/boost immunization with the BN-CV301 vaccine promotes activation of immune responses that provide a clinical benefit to cancer patients. This viral platform may be used to harbor different antigens and prime tumor immunity potentially useful for combinatorial strategies.
Clinical Cancer Research Online First Articles
4h
HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma
Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used multi-omics approaches and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance. Experimental Design: Mass spectrometry-based proteomics and RNA-Seq was used to identify the signaling pathways involved in the escape of uveal melanoma cells from MEK inhibitor therapy. Mechanistic studies were...
Clinical Cancer Research Online First Articles
4h
Sensitive and quantitative probing of pseudouridine modification in mRNA and long non-coding RNA [Method]
Pseudouridine () is the most abundant RNA modification in cellular RNA present in tRNA/rRNA/snRNA and also in mRNA and long non-coding RNA. Elucidation of function in mRNA/lncRNA requires mapping and quantitative assessment of its modification fraction at single-base resolution. The most widely used mapping method for mRNA/lncRNA relies on its reaction with N-Cyclohexyl-N'-(2-morpholinoethyl)carbodiimide (CMC), forming an adduct with the base in RNA that is detectable by reverse transcription...
RNA In Advance
4h
Anti-Leukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
In B cell acute lymphoblastic leukemia (B-ALL), activation of Notch signaling leads to cell-cycle arrest and apoptosis. We aimed to harness knowledge acquired by understanding a mechanism of Notch-induced cell death to elucidate a therapeutically viable target in B-ALL. To this end, we identified that Notch activation suppresses Polo-like kinase 1 (PLK1) in a B-ALL specific manner. We identified that PLK1 is expressed in all subsets of B-ALL, and is highest in Philadelphia-like (Ph-like) ALL,...
Molecular Cancer Therapeutics Online First Articles
5h
MEN1309/OBT076, a first-in-class Antibody-drug Conjugate (ADC) targeting CD205 in solid tumors.
CD205 is a type I transmembrane glycoprotein, member of C-type lectin receptor family. Analysis by mass spectrometry revealed that CD205 was robustly expressed and highly prevalent in a variety of solid malignancies from different histotypes. Immunohistochemistry (IHC) confirmed the increased expression of CD205 in pancreatic, bladder and triple negative breast cancer (TNBC) compared to that in the corresponding normal tissues. Using immunofluorescence microscopy, rapid internalization of the CD205...
Molecular Cancer Therapeutics Online First Articles
5h
Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies
Opinion statement The thymus is a key organ involved in establishing central immune tolerance. Thymic epithelial tumors (TETs) include thymomas and thymic carcinomas. Thymomas, which are histologically distinct from thymic carcinomas, lead to dysregulated thymopoiesis via decreased thymic epithelial expression of AIRE and MHC Class II, as well as via alterations in thymic architecture, thereby resulting in autoimmune complications that manifest as paraneoplastic disorders (PNDs)....
Current Treatment Options in Oncology
5h
Psychometric Properties of the MICRA Questionnaire in Portuguese Individuals Carrying SDHx Mutations
Abstract This study aims to present the translation and cultural adaptation, as well as the psychometric characteristics of the Portuguese version of the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire in individuals with SDHx mutations. The questionnaire was translated and culturally adapted in accordance with the process recommended by the World Health Organization. As per suggestion of the authors of the original instrument, a joint, universal European...
Journal of Cancer Education
9h
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi) remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma. Here, we explored the role of miRNAs in melanoma acq...
Journal of Experimental & Clinical Cancer Research - Latest Articles
10h
Body Fat and Risk of Breast Cancer in Postmenopausal Women: What Is the Truth?
Pathology & Oncology Research
13h
Awake surgery for glioblastoma can preserve independence level, but is dependent on age and the preoperative condition
Abstract Purpose Lately, awake surgery has been frequently adapted for glioblastoma (GBM). However, even with awake surgery, the expected long-term independence levels may not be achieved. We studied the characteristics of independence levels in GBM patients, and investigated the usefulness and parameter thresholds of awake surgery from the standpoint of functional outcomes. ...
Neuro-Oncology
14h
Outcomes after craniotomy for resection of craniopharyngiomas in adults: analysis of the National Surgical Quality Improvement Program (NSQIP)
Abstract Purpose Craniopharyngiomas occur in suprasellar locations that pose challenges for surgical management. This study evaluates the incidence of complications following craniotomy for craniopharyngioma in adults and investigates risk factors for these complications. Methods Patients who underwent craniotomy for excision of craniopharyngioma were identified...
Neuro-Oncology
14h
Cancers, Vol. 11, Pages 872: Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
Cancers, Vol. 11, Pages 872: Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic AgentCancers doi: 10.3390/cancers11060872Authors: Broos Lecocq Xavier Bridoux Nguyen Corthals Schoonooghe Lion Raes Keyaerts Devoogdt BreckpotThe PD-1:PD-L1 immune checkpoint axis is central in the escape of cancer cells from anticancer immune responses. Monoclonal antibodies (mAbs) specific for PD-L1 have been approved for treatment of various cancer types. Although PD-L1 blockade...
Cancers
15h
The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History
Abstract Tumor infiltrating lymphocytes (TIL), programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) expression are important prognostic markers. This study aimed to investigate these markers in lung adenocarcinoma (ADC) biopsies from patients with stage IIIB or IV ADC with little or no smoking history, to investigate their prognostic value and to correlate these results with the presence of driver mutations in the tumors. TIL were retrospectively evaluated on hematoxylin...
Pathology & Oncology Research
15h
Adjuvant therapy in renal cell carcinoma
Localized renal cell carcinoma (RCC) has an associated risk of recurrence after nephrectomy. Several clinical risk models attempt to predict oncologic outcomes based on clinical and pathologic features. In addition, novel gene signatures have been developed to refine risk prediction based on tumor biology. Systemic therapies targeting angiogenic pathways that are effective in metastatic RCC failed to show an improvement in overall survival in the adjuvant setting. Immune checkpoint inhibitors have...
Cancer
17h
Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high‐risk endometrial cancer: A prospective study
Background The identification of extrauterine disease is critical to the management of patients with high‐risk endometrial cancer. The purpose of the current study was to determine the accuracy of preoperative positron emission tomography (PET)/computed tomography (CT) in the detection of extrauterine disease. Methods Women with high‐risk endometrial cancer were enrolled prospectively and underwent preoperative PET/CT followed by surgery, including sentinel lymph node biopsy and lymphadenectomy....
Cancer
17h
Cancers, Vol. 11, Pages 867: Nobiletin and Derivatives: Functional Compounds from Citrus Fruit Peel for Colon Cancer Chemoprevention
Cancers, Vol. 11, Pages 867: Nobiletin and Derivatives: Functional Compounds from Citrus Fruit Peel for Colon Cancer ChemopreventionCancers doi: 10.3390/cancers11060867Authors: Goh Tan Goh Chan Pusparajah Lee GohThe search for effective methods of cancer treatment and prevention has been a continuous effort since the disease was discovered. Recently, there has been increasing interest in exploring plants and fruits for molecules that may have potential as either adjuvants or as chemopreventive agents...
Cancers
17h
Cancers, Vol. 11, Pages 870: Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles
Cancers, Vol. 11, Pages 870: Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold NanoparticlesCancers doi: 10.3390/cancers11060870Authors: Cruz KayserNanoparticle carriers offer the possibility of enhanced delivery of therapeutic payloads in tumor tissues due to tumor-selective accumulation through the enhanced permeability and retention effect (EPR). Gold nanoparticles (AuNP), in particular, possess highly appealing features for development as nanomedicines, such as...
Cancers
17h
Cancers, Vol. 11, Pages 868: Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
Cancers, Vol. 11, Pages 868: Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic ActivitiesCancers doi: 10.3390/cancers11060868Authors: Tura Pawlik Rudolf Ernesti Stutzer Grisanti RanjbarDespite the implication of vascular endothelial growth factor-A (VEGF-A) in the pathophysiology of uveal melanoma (UM), the anti-VEGF-A antibody bevacizumab yielded conflicting results on UM growth. Here, we evaluated whether bevacizumab...
Cancers
17h
Cancers, Vol. 11, Pages 869: Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images
Cancers, Vol. 11, Pages 869: Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT ImagesCancers doi: 10.3390/cancers11060869Authors: Fiz Dittmann Campi Weissinger Sahbai Reimold Stenzl Piana Sambuceti la FougèreTo meet the current need for skeletal tumor-load estimation in castration-resistant prostate cancer (CRPC), we developed a novel approach based on adaptive bone segmentation. In this study, we compared the program output with existing...
Cancers
17h
Cancers, Vol. 11, Pages 871: Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin
Cancers, Vol. 11, Pages 871: Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/CisplatinCancers doi: 10.3390/cancers11060871Authors: Takeuchi Jaffer A Fang Pfeiffer Takeuchi van Laarhoven The Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study (FLAGS) and the Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST) have shown that...
Cancers
17h
Pre-radiotherapy daily exercise training in non-small cell lung cancer: A feasibility study
Publication date: July–August 2019Source: Reports of Practical Oncology & Radiotherapy, Volume 24, Issue 4Author(s): Trine Egegaard, Julie Rohold, Christian Lillelund, Gitte Persson, Morten QuistAbstractAimTo examine the feasibility of an individual, supervised, structured moderate-to-high intensity cycle ergometer exercise training immediately before radiotherapy in patients undergoing concomitant chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC).BackgroundLung cancer...
Reports of Practical Oncology & Radiotherapy
17h
The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review
Publication date: August 2019Source: European Journal of Cancer, Volume 117Author(s): Luca Mazzarella, Bruno Achutti Duso, Dario Trapani, Carmen Belli, Paolo D'Amico, Emanuela Ferraro, Giulia Viale, Giuseppe CuriglianoAbstract'First-generation' immune checkpoint inhibitors targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Programmed death-ligand 1 (PD(L)1) have undoubtedly revolutionised the treatment of multiple cancers in the advanced setting. Targeting signalling pathways other than core...
European Journal of Cancer
18h
Cancer risk in patients with Parkinson's disease in South Korea: A nationwide, population-based cohort study
Publication date: August 2019Source: European Journal of Cancer, Volume 117Author(s): Joo-Hyun Park, Do-Hoon Kim, Yong-Gyu Park, Do-Young Kwon, Moonyoung Choi, Jin-Hyung Jung, Kyungdo HanAbstractIntroductionThe association between Parkinson's disease (PD) and cancer development is controversial, especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the overall cancer risk and risk for specific cancers in patients with PD in Korea.MethodsUsing data from the...
European Journal of Cancer
18h
Long-term excess risk of breast cancer after a single breast density measurement
Publication date: August 2019Source: European Journal of Cancer, Volume 117Author(s): Matejka Rebolj, Oleg Blyuss, Kee Seng Chia, Stephen W. DuffyAbstractAimBreast density is a risk factor for breast cancer. As density changes across a woman's life span, we studied for how long a single density measurement taken in (post-)menopausal women remains informative.MethodsWe used data from Singaporean women who underwent a single mammography screen at age 50–64 years. For each case with breast cancer diagnosed...
European Journal of Cancer
18h
Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?
Publication date: August 2019Source: European Journal of Cancer, Volume 117Author(s): Carmen Criscitiello, Giuseppe Curigliano
European Journal of Cancer
18h
Opportunities for improving the efficiency of keratinocyte carcinoma care in primary and specialist care: Results from population-based Dutch cohort studies
Publication date: August 2019Source: European Journal of Cancer, Volume 117Author(s): M. Wakkee, S. van Egmond, M. Louwman, P. Bindels, J. van der Lei, T. Nijsten, L. HollesteinAbstractBackgroundHigh incidence rates of keratinocyte carcinoma (KC) in Western countries put pressure on healthcare systems. The aim of this study was to describe clinical practice in order to identify areas for improvement.MethodsA random selection of patients from the Integrated Primary Care Information database who consulted...
European Journal of Cancer
18h
Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Publication date: Available online 21 June 2019Source: European Journal of Surgical OncologyAuthor(s): Mohammad Alyami, Frederic Mercier, Matthieu Siebert, Pierre-Emmanuel Bonnot, Nathalie Laplace, Laurent Villeneuve, Guillaume Passot, Olivier Glehen, Naoual Bakrin, Vahan KepenekianAbstractBackgroundPIPAC is a recent method of intraperitoneal chemotherapy. The aim of this study was to describe the clinical characteristics of the patients who became amenable to CRS & HIPEC after PIPAC treatment.MethodsAll...
European Journal of Surgical Oncology (EJSO)
19h
Disparity in the use of adjuvant radioactive iodine ablation among high-risk papillary thyroid cancer patients
Publication date: Available online 20 June 2019Source: European Journal of Surgical OncologyAuthor(s): Ambria S. Moten, Huaqing Zhao, Charles M. Intenzo, Alliric I. WillisAbstractBackgroundWe sought to identify treatment disparities existing prior to publication of the 2015 American Thyroid Association Management Guidelines in order to identify patients with papillary thyroid cancer (PTC) at risk for receiving inadequate treatment.MethodsPatients diagnosed with PTC from 2011 to 2013 were identified...
European Journal of Surgical Oncology (EJSO)
19h
Cancers, Vol. 11, Pages 866: Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
Cancers, Vol. 11, Pages 866: Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung AdenocarcinomasCancers doi: 10.3390/cancers11060866Authors:Chien-Hung GowMin-Shu HsiehYen-Ting LinYi-Nan LiuJin-Yuan ShihBRAF V600E mutation, a missense mutation in exon 15 resulting in valine substitution for glutamate at position 600 within the kinase domain of BRAF oncogene, is found in a subset of lung adenocarcinoma (ADC). The usefulness of immunohistochemistry (IHC) as an alternative...
Cancers
19h

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Αναζήτηση αυτού του ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader